SUMMARY Five infants with hypoglycaemia due to hyperinsulinism were treated for between three and 11 days with a somatostatin analogue, which raised the mean blood glucose concentration and lowered the glucose requirements in all. Somatostatin analogue appears to be useful in the short term management of these patients. 
The prompt and effective treatment of hypoglycaemia due to hyperinsulinism reduces substantially the risk of long term neurological sequelae.' Glucose alone, even in high concentrations, may often fail to maintain blood glucose concentrations within the normal range and other measures are required to reduce the excessive concentrations of insulin.'
Diazoxide has been used but this drug has major side effects and may be ineffective, especially in younger patients. Natural sequence somatostatin reduces insulin concentrations but its therapeutic use is limited by its half life of only two to three minutes so that it is necessary to administer it by continuous intravenous infusion. 2 We have used long acting somatostatin analogue (SMS 201-995, Sandoz), which is more potent and specific than the natural peptide and can be given by subcutaneous injection, to treat five patients with hypoglycaemia due to hyperinsulinism.
Patients and methods All patients were girls: four presented within a few hours of birth; the fifth presented at 9 months of age but gave a history from birth of hypoglycaemic symptoms, which had responded to two hourly feeds both day and night. Birth weights were above the 50th centile for gestational age ( 
Results
A test dose of somatostatin analogue (1-0 rig) was administered subcutaneously to patient 1. Within minutes there was a rapid rise in blood glucose concentration and a concomitant reduction in glucose requirements, with the effect waning after four to five hours. 4 Somatostatin analogue was then administered subcutaneously in three to four doses per day, commencing at 1-0 [tg/kg/dose, but subsequently titrating the dosage against response, for a total of three to 11 days. Increasing doses of analogue led to a fall in glucose requirements (although never into the normal range for infants of 4-6 mg/kg/minute) and to a reduction of glucose oscillation. All patients continued to require intravenous treatment.
The figure (a) shows that in all patients the mean 24 hour blood glucose concentration rose after the administration of somatostatin analogue (4-9 tg/kg/ day). The change in mean 24 hour blood glucose concentrations was significant (Wilcoxon's paired test; p<005), although the change in glucose oscillation was not. Glucose requirements fell significantly (p<005) ( figure (b) ). 
Discussion
Somatostatin analogue was effective in the short term management of patients with hypoglycaemia due to hyperinsulinism. We use it to stabilise blood glucose concentrations and to enable lower concentrations of glucose to be used both preoperatively and perioperatively. Given by regular subcutaneous injection its dosage regimen can be easily titrated against response and its short onset of action enables it to be of use in the emergency management of these patients, such as in the resiting of drips.
There are some theoretical reservations about the long term administration of somatostatin analogue to children as it has profound effects on many other hormones.5 6 
